Sign in
Taking people in South KoreaNo phase

Observing a combined blood pressure pill in Korean people with hypertension

Observes amlodipine, losartan and chlorthalidone in Korean people with hypertension.

Key facts

Who runs it
Hanmi Pharmaceutical Company Limited
Where
Gyeonggi-do, South KoreaSee the site
Trial code
Registry title
Effectiveness and Safety of Sequential Triple Combination Therapy (Amlodipine/Losartan/Chlorthalidone) in Korean Patients With Hypertension
Status
Recruiting
People taking part
3,500 people, planned
Started
19 Mar 2026
Expected to end
31 Aug 2028
Type of study
Observational
Treatments tested
  • AMOPREL TAB 1.67/16.67/4.17mg
Record updated
25 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for Korean adults with high blood pressure, either newly diagnosed or taking one blood pressure drug, whose doctor has decided to give Amoprel tablets.

Age
19 years or older
Sex
All sexes can join.
Disease stage
High blood pressure (hypertension), newly diagnosed or currently treated with a single blood pressure drug.
Earlier treatment
People already on blood pressure treatment must be taking only one blood pressure drug.

Main reasons for not taking part

  • Has a reason that rules out Amoprel Tab. or Amozartan Plus Tab. listed in their usage precautions
  • Pregnant, possibly pregnant, or breastfeeding
  • Currently taking part in an interventional study
  • The researcher judges the person not fit to take part for other reasons

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Korean patients aged 19 years or older diagnosed with hypertension
  • Individuals newly diagnosed with hypertension or currently taking a single antihypertensive drug
  • Individuals for whom administration of Amoprel tablets has been determined based on the researcher's medical judgment
  • Individuals who have heard an explanation of this study and have voluntarily given written consent to participate in the study

Who cannot take part

  • Individuals falling under the contraindications listed in the precautions for use of Amoprel Tab. or Amozartan Plus Tab
  • Pregnant women, women who may be pregnant, and nursing mothers
  • Individuals currently participating in an interventional study
  • Individuals deemed unsuitable for participation in this study by the researcher for other reasons

Where in South Korea

  • Yongin Severance HospitalGyeonggi-do, South KoreaContact: PMTaking people

About the trial

What the trial wants to find out

A multicenter, prospective, non-interventional, observational study to evaluate effectiveness and safety of sequential triple combination therapy (amlodipine/losartan/chlorthalidone) in Korean patients with hypertension

Treatments tested

  • AMOPREL TAB 1.67/16.67/4.17mg

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multicenter, Prospective, Non-interventional, Observational Study to Evaluate Effectiveness and Safety of Sequential Triple Combination Therapy (Amlodipine/Losartan/Chlorthalidone) in Korean Patients With Hypertension
Plain-language title
Observing a combined blood pressure pill in Korean people with hypertensionGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Record updated
25 August 2026